A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602)

Interventions: The dose of denosumab (Prolia) is 60mg administered as a single subcutaneous injection within a week before the induction of chemotherapy. All participants should receive adequate calcium and vitamin D supplementation.
Primary outcome(s): To investigate the efficacy of denosumab for preventing a bone mineral density reduction 16 weeks after induction of chemotherapy.
Study Design: Single arm Non-randomized